• RCKT is trading at $3.55 (up 5.3%) in pre-market, extending its rebound following the recent FDA accelerated approval of Kresladi, its first commercial gene therapy, for severe LAD-I.
  • The approval, announced on June 28, also granted Rocket Pharmaceuticals a Rare Pediatric Disease Priority Review Voucher, which was subsequently monetized for $180 million, strengthening the company's balance sheet.
  • This significant regulatory milestone and the associated financial boost are key drivers behind the stock's current positive price action.